CV6 Therapeutics
1 known investors
CV6 Therapeutics develops investigational cancer therapies designed for combination use with established standards of care, with a lead program (CV6-168) intended to enhance the activity of 5-fluorouracil and other thymidylate synthase-targeted therapies. The company is advancing CV6-168 through Phase 1a clinical development.
Founders & leadership
RD
Robert D. LadnerCEO & Founder
Investors · 1
Frequently asked questions
- What does CV6 Therapeutics do?
- CV6 Therapeutics develops investigational cancer therapies designed for combination use with established standards of care, with a lead program (CV6-168) intended to enhance the activity of 5-fluorouracil and other thymidylate synthase-targeted therapies. The company is advancing CV6-168 through Phase 1a clinical development.
- Who founded CV6 Therapeutics?
- CV6 Therapeutics was founded by Robert D. Ladner.
- Who are CV6 Therapeutics's investors?
- CV6 Therapeutics's investors include Clarendon Fund Managers Ltd..